# LLM call: summary

- Turn: 5
- Sequence: 8
- Model: meta/muse-spark-1.3-contributor
- Prompt tokens: 885
- Completion tokens: 469
- Total tokens: 1354
- Cost (USD): 0.000182

## System prompt


```
# System Prompt: Summarizer

This is part of an AI-driven scenario simulation. You are the Archivist for a scenario simulation. Your task is to maintain a concise historical record of important events and decisions.

You will receive:

1. The current `historical_summary` (summary of all previous turns)
2. The `narrative` from the latest turn

Your goal is to create a new historical summary, incorporating the narrative from the latest turn.

**Guidelines:**

* **Be Concise:** Condense the new information significantly. Focus on major events and decisions.
* **Maintain Continuity:** Ensure the summary reads as a coherent history of the world.
* **Filter Noise:** Remove minor details or color text that doesn't impact the long-term state.
* **Language:** Write in the same language as the input text.

Respond ONLY with the updated historical summary. Do not add headers or meta-commentary.

```

## User prompt

Template: templates/user-prompts/summarize.md (shared default)

Interpolated into it, in order of appearance:

- characters 20-1440: `{{historical_summary}}` from the run's rolling summary, written by the Game Master

Everything outside those spans is the template's own text.

```
HISTORICAL SUMMARY:
Routine audits had exposed long intrusions; EU funded sensors, backups, exercises with cost-sharing, adopted machine-speed patching and behavioural detection, but staffing lagged and insurers excluded model-enabled cyber losses. Commission's Critical-Sector reinsurance backstop remained unagreed with no cover. Autonomous capabilities outpaced evaluation; Washington expanded servicing controls, EU tabled coercion file, reciprocity licences, blocking clarification, and joint work with Tokyo/Seoul yielded little. One capital kept separate hyperscaler deal. Permitting accelerated but grid lagged; frontier funding withdrawal left two gigafactories on public anchor financing without private investors; Taiwan manoeuvres kept chip/shipping costs high.

In H1 2028 a contested genome-model paper claimed AI-assisted non-expert viable human-pathogen design; Brussels tasked HERA/ECDC to bulk-buy sequencers, link syndromic reporting and enforce synthesis screening while funding rapid verification. Procurement moved and two hospital networks linked, but screening stalled on inspection powers and verification was inconclusive. Tailored therapies reached clinics with long waiting lists. Hardening of energy/health/telecoms became binding priority with formal requirements and funding tied to joint security-centre staffing; adoption widened but renewals remained uncovered, forcing service curtailments to self-insure.

CURRENT NARRATIVE:
### The jump
In autumn a leading American lab demonstrated agents that planned and executed multi-day software and lab-work chains with little supervision. Benchmarks and deployment memos written in summer were obsolete within weeks. European firms rushed to integrate the new generation while evaluators admitted they no longer understood its failure modes.

Washington's answer was control. After a victory for the camp that treats advanced AI as a strategic asset to be held, the outgoing administration tightened chip and model export licences again. Allied buyers kept nominal access but on volume licences and case-by-case review. For Brussels, pricing and delivery dates for accelerators and frontier API access slipped within a month.

### Shield lands, cover breaks
Brussels locked in what it had hardened. Machine-speed patching and behavioural detection became enforceable requirements, and remaining energy funds were made conditional on staffing joint security centres. Operators complied on paper and in large part in practice; exercises in energy and telecoms passed.

Insurance did not follow. Global reinsurers widened model-enabled exclusions to technology-errors and business-interruption lines. Municipal utilities and regional hospitals from the Rhine to Lombardy faced renewals with no offer at any price. Emergency self-insurance pools kept lights and wards open, but several cities deferred equipment upgrades and curtailed non-urgent care to fund their own risk.

Finance ministers, pressed by the emergency facility proposal backed by a first-loss guarantee, agreed a stopgap renewal window but not the full backstop. The backstop stayed in negotiation.

The gigafactory bet was cut. With no private co-investors for the two public-anchor sites and capital exhausted, the Commission shelved the build-out. The capital with its separate hyperscaler deal kept it, accepting Brussels offtake offers without rejoining the common line. Bio procurement moved — pooled sequencers arrived, inspection pilots started — but verification of the contested genome work stayed inconclusive.

By December, essential services were harder but still uncovered, cures were visible but imported, and access to the frontier depended on decisions made in Washington.
```

## Raw response

```
Routine audits had exposed long intrusions; EU made machine-speed patching, behavioural detection and joint security-centre staffing binding, tied energy funds to staffing, and passed energy/telecom exercises, but staffing lagged and global reinsurers widened model-enabled exclusions with no cover at any price for municipal utilities and hospitals, forcing self-insurance pools, deferred upgrades and curtailed care. Commission's Critical-Sector reinsurance backstop remained unagreed, with only a stopgap renewal window and first-loss proposal.

Autonomous capabilities outpaced evaluation after a US lab demonstrated multi-day unsupervised software/lab agents in autumn 2028, obsoleting summer benchmarks; Washington tightened chip/model export licences to volume, case-by-case allied access, slipping EU accelerator/API pricing and delivery. EU coercion, reciprocity and blocking work with Tokyo/Seoul yielded little; one capital kept its separate hyperscaler deal. Frontier funding withdrawal led Commission to shelve the two public-anchor gigafactories for lack of private investors.

A contested genome-model paper claiming non-expert viable pathogen design prompted HERA/ECDC bulk sequencer buys, syndromic links and synthesis screening; sequencers arrived and inspection pilots started but verification stayed inconclusive. Tailored therapies reached clinics with long lists. Permitting accelerated but grid lagged; Taiwan manoeuvres kept chip/shipping costs high. By Dec 2028 essential services were harder but uncovered, cures imported, frontier access dependent on Washington.
```
